Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ambrilia Biopharma licensed ZBx, an option to take over irrevocable and exclusive worldwide rights to its proprietary PSP-94 reagents and related intellectual property (PSP-94).
Subscribe to our email newsletter
Under the agreement, ZBx can exercise its option during a period which starts 90 days from, and expires 120 days after, the effective date of the Option.
If ZBx exercises such option, Ambrilia will be entitled to obtain up to a total of $50,000 upon signing of a definitive agreement and achievement of sales milestones, as well as royalties on sales and a percentage share of proceeds from any sublicenses or sale of PSP-94 by ZBx.
Additionally, ZBx is expected to take up all future costs linked with the further development, manufacturing and commercialization of PSP-94.